← Oncology Approval Tracker

FDA DECISION ·

Truqap + abiraterone + prednisone

capivasertib with abiraterone and prednisone · AstraZeneca

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with PTEN deficiency identified by an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

This introduces PTEN deficiency as a way to select patients for an AKT inhibitor regimen in earlier metastatic prostate cancer.

What research teams should watch

Confirm the PTEN assay and scoring result. Build glucose monitoring and other regimen safety checks into the documentation for patients receiving the combination.

Clinical operations takeaway

Build specimen status, the assay report, and the review handoff into the screening checklist. Define who follows up when a report is missing or the result needs clarification.

Plan biomarker screening and specimen workflows

PRIMARY RECORDS

Sources